Lymphoma, Large B-Cell, Diffuse: all 1,432 studies
Page 9 of 15. Open to participants first (359), then studies with results posted, then the rest; newest registration first within each.
- Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin LymphomaStatus unknownNCT05164770Phase 3
- Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLLTerminatedNCT05153330Phase 1
- A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)CompletedNCT05144841Phase 2
- Study of XL114 in Subjects With Non-Hodgkin's LymphomaTerminatedNCT05144347Phase 1
- Characterisation of TIM-3/Gal-9 Immune Checkpoints in Primary Central Nervous System Diffuse Large B Cell LymphomasCompletedNCT05133505
- CAR T Cell Therapy Related Cardiovascular OutcomesCompletedNCT05130489
- Combining Intratumoral Metabolic Heterogeneity and Dissemination Feature (Dmax) on 18F-FDG PET/CT Improves Prognosis Prediction in DLBCLCompletedNCT05113576
- Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin LymphomaStatus unknownNCT05097443Phase 3
- Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBLStatus unknownNCT05050630Phase 2
- Imaging Apoptosis for Lymphoma Treatment ResponseTerminatedNCT05048732Early Phase 1
- A Study Comparing the Efficacy and Safety Between H-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma PatientsStatus unknownNCT05040906Phase 3
- Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)Status unknownNCT05039658Phase 1
- Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNSTerminatedNCT05022797Phase 2
- Polatuzumab Vedotin in Patients With Relapsed and Refractory Diffuse Large B Cell LymphomaCompletedNCT05006534
- CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHLWithdrawnNCT04995536Phase 1
- Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort StudyTerminatedNCT04982471
- realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCLCompletedNCT04981795
- Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop StudyActive, not recruitingNCT04978584Phase 2
- A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)WithdrawnNCT04974996Phase 1
- Study for Late Assessment of the Safety and Efficacy of Biosimilar RituximabCompletedNCT04928573
- A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)Active, not recruitingNCT04914741Phase 1/2
- the Effect of Broken Ganoderma Lucidum Spore Powder on Quality of Life and Immune Function in Patients With Diffuse Large B-cell Lymphoma After ChemotherapyStatus unknownNCT04914143Not applicable
- Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T CellsActive, not recruitingNCT04911478
- Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin LymphomaTerminatedNCT04903197Phase 1
- Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS StudyCompletedNCT04890236Early Phase 1
- Living Conditions of Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma in the Côte d'Or RegionCompletedNCT04859920
- Immune Responses to COVID-19 Vaccination in Lymphoma PatientsCompletedNCT04858568
- Ph I/II Study of E7777 Prior to CAR-T for R/R LBCLSuspendedNCT04855253Phase 1/2
- Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell LymphomaActive, not recruitingNCT04850495Phase 1
- RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid MalignanciesTerminatedNCT04844086Phase 1
- Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell LymphomaCompletedNCT04833504
- Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)CompletedNCT04833114Phase 3
- A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell LymphomaStatus unknownNCT04827004Phase 2
- Gene Abnormalities and Prognosis in Diffuse Large B-cell LymphomaStatus unknownNCT04825899
- Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL PatientsActive, not recruitingNCT04824092Phase 3
- CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell LymphomaCompletedNCT04812691Phase 1
- Secondary Prognostic Index in RefrActory LymphomaStatus unknownNCT04804865
- PD-1 Inhibitor Tislelizumab Maintenance Therapy in R/R DLBCL Patients After ASCTStatus unknownNCT04799314Phase 3
- Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell LymphomaActive, not recruitingNCT04799275Phase 2/3
- Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCLStatus unknownNCT04796857Phase 1/2
- A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)TerminatedNCT04790903Phase 1
- PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCTStatus unknownNCT04789434Phase 3
- CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PMLActive, not recruitingNCT04787263Phase 1/2
- A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced MalignanciesCompletedNCT04772989Phase 1
- Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic MalignanciesStatus unknownNCT04767308Early Phase 1
- Tumor Heterogeneity in Diffuse Large B-cell Lymphoma in Relation to CNS Involvement and Cell-free DNACompletedNCT04763148
- First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ MalignanciesStatus unknownNCT04763083Phase 1
- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell LymphomaActive, not recruitingNCT04739813Phase 1
- A Phase 1 Study of ADI-001 in B Cell MalignanciesTerminatedNCT04735471Phase 1
- DLBCL Treatment in Children and AdolescentsCompletedNCT04726995
- RadiothErapy priMIng for CAR-TActive, not recruitingNCT04726787Not applicable
- Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaNo longer availableNCT04705454
- Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCLCompletedNCT04697160
- Single-Cell Map of Immune and Lymphoma Cells in B-cell Non-Hodgkin's LymphomaCompletedNCT04696692Not applicable
- The Potential of Patient-reported Outcome Measures in Detection of Relapse in Diffuse Large B-cell LymphomaCompletedNCT04695366
- Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell LymphomaSuspendedNCT04668365Phase 2
- Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)Active, not recruitingNCT04663347Phase 1/2
- Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell LymphomaCompletedNCT04661943Phase 2
- A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaCompletedNCT04657302Phase 1
- A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)Active, not recruitingNCT04628494Phase 3
- A Novel Prognostic Model of NPI for Risk-Predicting and Clinical Decision-making in Diffuse Large B-Cell Lymphoma in the Rituximab EraStatus unknownNCT04624971
- A Multicenter, Retrospective Observational Study to Evaluate the Effectiveness and Safety of Polatuzumab VedotinStatus unknownNCT04624893
- Lenalidomide Combined With Rituximab as Front-line Therapy for DLBCL Patients Aged Over 80 YearsStatus unknownNCT04622579Phase 2
- A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma （DLBCL）Status unknownNCT04610970Phase 2
- Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)WithdrawnNCT04607772Phase 1/2
- Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.Active, not recruitingNCT04604067Phase 2
- A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin LymphomaActive, not recruitingNCT04594642Phase 1
- Copanlisib Plus Venetoclax in R/R DLBCLActive, not recruitingNCT04572763Phase 1/2
- Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)Active, not recruitingNCT04546620Phase 2
- Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell LymphomaStatus unknownNCT04544059Phase 2
- Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)Active, not recruitingNCT04542824Phase 1/2
- POLA+BR for Relapsed or Refractory DLBCLWithdrawnNCT04535102Phase 2
- A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)Active, not recruitingNCT04529772Phase 3
- Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin LymphomaActive, not recruitingNCT04526834Phase 1
- Telemedicine for Early Detection of Cytokine Release Syndrome and NeurotoxicityWithdrawnNCT04503538Not applicable
- Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLLStatus unknownNCT04502394Phase 1/2
- YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical TrialStatus unknownNCT04500561Phase 1/2
- Long-term Follow-up Study for Patients Treated With CLBR001 CAR-TCompletedNCT04488354Phase 1
- An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells InjectionStatus unknownNCT04486872Phase 1
- Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated LymphomaActive, not recruitingNCT04479267Phase 2
- Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCLStatus unknownNCT04476459Phase 1/2
- 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell CancersActive, not recruitingNCT04464200Phase 1
- Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)Active, not recruitingNCT04460248Phase 2
- Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)WithdrawnNCT04456023Phase 2
- CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell MalignanciesCompletedNCT04450069Phase 1
- LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)Active, not recruitingNCT04446962Phase 1/2
- A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaActive, not recruitingNCT04442022Phase 2/3
- A Study of ICP-022 in Patients With R/R DLBCLCompletedNCT04438005Phase 2
- Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell LymphomaTerminatedNCT04433182Phase 2
- Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell LymphomaStatus unknownNCT04432402Not applicable
- Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell LymphomaStatus unknownNCT04425824Phase 2
- Predictive Value of a mRNA Signature and Liquid Biopsy in Diffuse Large B Cell LymphomaStatus unknownNCT04423549
- Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell TherapyCompletedNCT04409314
- A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell LymphomaActive, not recruitingNCT04408638Phase 3
- Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell LymphomaActive, not recruitingNCT04384484Phase 3
- CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell LymphomaStatus unknownNCT04381741Phase 1
- A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCLCompletedNCT04361279Phase 3
- Follow-up Study of SyB L-0501 in Combination With Rituximab to Treat DLBCLCompletedNCT04354402
- Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell LymphomaActive, not recruitingNCT04323956Phase 1
- TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic LeukemiaCompletedNCT04323657Phase 1/2